MinorDirect thrombin inhibitor×Second-generation antihistamine
Updated · Methodology
Mechanism
Dabigatran etexilate is a substrate of the transporter P-glycoprotein (P-gp): P-gp inhibitors raise its levels and P-gp inducers lower them. Dabigatran is not metabolised by cytochrome P450 enzymes and has no effect on them (dabigatran SmPC, European Medicines Agency, EMA; Pradaxa label, US Food and Drug Administration, FDA). In laboratory studies, desloratadine is neither a substrate nor an inhibitor of P-gp, and in vivo it does not inhibit CYP3A4 (desloratadine SmPC, EMA). The enzyme that metabolises desloratadine has not yet been identified, so some interactions cannot be fully excluded, but the elimination of dabigatran does not depend on enzymes (desloratadine and dabigatran SmPCs, EMA). No document names the pair.
Symptoms
The documents describe no symptoms linked to this combination. The main risk of dabigatran is bleeding, including severe gastrointestinal bleeding, especially in people aged 75 years or older. An unexplained fall in haemoglobin, haematocrit or blood pressure calls for a search for a bleeding site (dabigatran SmPC, European Medicines Agency, EMA). The most common adverse effects of desloratadine are fatigue, dry mouth and headache. Dizziness, somnolence and seizures are very rare (desloratadine SmPC, EMA).
Management
According to the documents, the combination is acceptable, and the doses of dabigatran and desloratadine need no change. Desloratadine is not one of the P-glycoprotein inhibitors or inducers that change dabigatran levels (dabigatran and desloratadine SmPCs, European Medicines Agency, EMA; Pradaxa label, US Food and Drug Administration, FDA). Before starting dabigatran, assess renal function as creatinine clearance (Cockcroft–Gault method) to exclude severe renal impairment with clearance below 30 mL/min. In people over 75 years or with mild or moderate renal impairment, repeat the assessment at least once a year (dabigatran SmPC, EMA). In severe renal impairment, use desloratadine with caution (desloratadine SmPC, EMA). During dabigatran treatment, watch for signs of bleeding and anaemia, especially when several risk factors are present, and interrupt dabigatran if severe bleeding occurs (dabigatran SmPC, EMA).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- FDA: Pradaxa (dabigatran etexilate) capsules prescribing information (2025)– FDA label, DailyMed setid ba74e3cd-b06f-4145-b284-5fd6b84ff3c9, sections 2.2, 5.5, 7.1–7.3, figure 3.1
- EMA: Ficha técnica: Desloratadina – Aerius (EU/1/00/160), sección 5.1 (2026)– EMA, SmPC Aerius 5 mg comprimidos recubiertos con película (EU/1/00/160), texto en CIMA nº 00160009, consultado 19/10/2026, sin fecha de revisión en CIMA, secciones 4.5, 4.8 y 5.1
- FDA: Clarinex (desloratadine) prescribing information (2025)– FDA, DailyMed setid c671342e-69a2-4ca5-abc2-8166ed4240d4 (Organon LLC), revisión 05/2025 (versión 6, texto revisado 06/2021), secciones 6.1, 7 y 12.1
- EMA: Ficha técnica: Dabigatrán etexilato, Pradaxa 150 mg (EU/1/08/442), sección 4.5 (2026)– EMA, Pradaxa 150 mg cápsulas duras (Boehringer Ingelheim International, autorización europea por procedimiento centralizado), ficha técnica en CIMA, nº registro 08442011, consultada 30.10.2026, sin fecha de revisión en CIMA, secciones 4.2, 4.3, 4.4 (tabla 4), 4.5 (tabla 8) y 4.8